In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

CRISPR screens are a powerful source of biological discovery, enabling the unbiased
interrogation of gene function in a wide range of applications and species. In pooled …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …

Standard first-line chemotherapy results in disease progression and death within one year in
most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Our understanding of the function of the transcriptional regulators YAP and TAZ (YAP/TAZ)
in cancer is advancing. In this Review, we provide an update on recent progress in YAP/TAZ …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …